A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT06165250

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06165250
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06165250. Randomized; double masking; primary purpose treatment. Start 2024-04-17 (actual); primary completion 2025-11-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
Condition
Essential Hypertension
Condition
Primary Hypercholesterolemia
Intervention (Drug)
BR1018A
Intervention (Drug)
BR1018A-1
Intervention (Drug)
BR1018B
Intervention (Drug)
BR1018B-1
Intervention (Drug)
BR1018C
Intervention (Drug)
BR1018C-1
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06165250
Content hash
7f073b37fbfa0e4e1ca463d06d6067b01987a9b33288ccef2b94841b9b253b85